Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali

CRL shall invest another Rs. 200 crore for creation of additional beds

Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr

Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025

Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA

Sun Pharma gets FDA approval for new device to treat skin disease

Punita Lal Joins Lupin Board as Additional Director

She has held senior positions at Coca-Cola in China and PepsiCo in India

Lupin receives USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr

The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025

Wanbury posts Q4 FY25 consolidated PAT at Rs. 20.25 Cr

The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025

Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr

The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025